刍议阿司匹林肠溶片联合阿托伐他汀钙片治疗冠状动脉粥样硬化性心脏病的疗效

Humble Opinion on the Efficacy of Aspirin Enteric-coated Tablets Combined with Atorvastatin Calcium Tablets in the Treatment of Coronary Atherosclerotic Heart Disease

目的探讨阿司匹林肠溶片联合阿托伐他汀钙片治疗冠状动脉粥样硬化性心脏病的疗效。方法选取2018年6月—2021年5月该院收治的冠状动脉粥样硬化性心脏病患者117例,按照随机数表法,分为对照组(n=58)与观察组(n=59)。全部患者均接受常规药物治疗,对照组加用阿司匹林肠溶片治疗,观察组在对照组基础上加用阿托伐他汀钙片治疗,比较两组临床疗效、血脂水平、炎性因子水平与不良反应发生率。结果观察组治疗总有效率为91.53%,高于对照组的77.59%,差异有统计学意义(χ^(2)=4.366,P=0.037);观察组治疗后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平低于对照组,高密度脂蛋白胆固醇(HDL-C)水平高于对照组,差异有统计学意义(t=12.257、22.765、19.604、4.135,P<0.05);观察组治疗后C反应蛋白(CRP)与肿瘤坏死因子-α(TNF-α)水平低于对照组,差异有统计学意义(t=6.894、15.386,P<0.05);两组不良反应发生率差异无统计学意义(χ^(2)=0.334,P=0.563)。结论阿司匹林肠溶片联合阿托伐他汀钙片治疗冠状动脉粥样硬化性心脏病的疗效确切,可降低血脂与炎性因子水平,且不会明显增加不良反应。

Objective To investigate the efficacy of aspirin enteric-coated tablets combined with atorvastatin calcium tablets in the treatment of coronary atherosclerotic heart disease.Methods A total of 117 patients with coronary atherosclerotic heart disease admitted to the hospital from June 2018 to May 2021 were selected and divided into the control group(n=58)and the observation group(n=59)according to the random number table method.All patients received conventional drug treatment,the control group was additionally treated with aspirin enteric-coated tablets,and the observation group was additionally treated with atorvastatin calcium tablets on the basis of the control group.The clinical efficacy,blood lipid levels,inflammatory factor levels and adverse events were compared between the two groups reaction rate.Results The total effective rate of the observation group was 91.53%,which was higher than 77.59%of the control group,the difference was statistically significant(χ^(2)=4.366,P=0.037).After treatment,the levels of total cholesterol(TC),triglyceride(TG),and low-density lipoprotein cholesterol(LDL-C)in the observation group were lower than those in the control group,the level of lipoprotein cholesterol(HDL-C)was higher than that of the control group,the difference was statistically significant(t=12.257,22.765,19.604,4.135,P<0.05).After treatment,the levels of C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)in the observation group were lower than those in the control group,the difference was statistically significant(t=6.894,15.386,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(χ^(2)=0.334,P=0.563).Conclusion Aspirin enteric-coated tablets combined with atorvastatin calcium tablets are effective in the treatment of coronary atherosclerotic heart disease,and can reduce the levels of blood lipids and inflammatory factors without significantly increasing adverse reactions.